摘要
二肽基肽酶Ⅳ(dipeptidyl peptidase Ⅳ,DPP-Ⅳ;EC3.4.14.5/CD26)属于丝氨酸肽酶中脯氨酸寡肽酶家族成员之一,是目前糖尿病新药研发的热点之一。体内外研究显示胰高血糖素样肽-1(GLP-1)具有较好的抗糖尿病效应,但是由于其体内被以DPP-Ⅳ为主的酶降解,半衰期仅2min,因而限制了其在临床上的应用。研究表明DPP-Ⅳ抑制剂能延长GLP-1在体内的半衰期,从而有效地降低血糖。
Dipeptidyl peptidase Ⅳ （dipeptidyl peptidase IV, DPP-IV; EC3.4.14.5/CD26） is an important target for the treatment of diabetes which is one kind of proline 01igopeptide of serine aminopeptidase. It has been showed that glucagon-like peptide-1 have significant hypoglycemic effects in vitro and in vivo. However, GLP-1 action has a very shot half life of about 2 min due to its degradation by DPP-Ⅳ, which limited its clinical application. DPP-Ⅳ inhibitors have been proved to prevent GLP-1 degradation and thus effectively
出处
《江西食品工业》
2012年第2期42-43,共2页
Jiangxi Food Industry
关键词
二肽基肽酶Ⅳ
抑制剂
药物筛选
降血糖
DPP Ⅳ decrease blood glucose. inhibitors
drug screening
antihyperglycemic
